Table 3.
Associations of vitamin D metabolic ratio (24,25[OH]2D3/25[OH]D3) with risk of ESRD and death in case cohort
| 24,25(OH)2D3/25(OH)D3 ratio | No. of events | Incidence rate (%/yr)a | HR (95% CI) model 1 |
HR (95% CI) model 2 |
HR (95% CI) model 3 (mediation) |
|---|---|---|---|---|---|
| ESRD | |||||
| Tertile 1 | 371 | 7.00 | 3.20 (2.41–4.27) | 0.88 (0.63–1.23) | 0.79 (0.55–1.16) |
| Tertile 2 | 225 | 4.42 | 1.90 (1.43–2.52) | 0.89 (0.64–1.26) | 0.75 (0.51–1.09) |
| Tertile 3 | 112 | 1.32 | Ref | Ref | Ref |
| Per 20 pg/ng (1 SD) decrement | 1.80 (1.56–2.08) | 0.94 (0.81–1.10) | 0.86 (0.72–1.02) | ||
| Death | |||||
| Tertile 1 | 278 | 4.80 | 1.10 (0.80–1.51) | 1.09 (0.79–1.50) | 1.06 (0.72–1.56) |
| Tertile 2 | 227 | 3.26 | 1.19 (0.89–1.58) | 1.15 (0.86–1.54) | 1.10 (0.78–1.55) |
| Tertile 3 | 145 | 1.49 | Ref | Ref | Ref |
| Per 20 pg/ng (1 SD) decrement | 1.18 (1.02–1.36) | 1.17 (1.01–1.36) | 1.18 (0.99–1.41) | ||
CI, confidence interval; ESRD, end-stage renal disease; HR, hazard ratio; Ref, reference.
Model 1: Adjusted for age, sex, race, diabetes, systolic blood pressure, number of antihypertensive medication classes, prevalent cardiovascular disease, smoking status, renin-angiotensin-aldosterone inhibitors, statin use, calciferol use, and vitamin D receptor activators.
Model 2: Model 1 + estimated glomerular filtration rate and urine protein-to-creatinine ratio.
Model 3: Model 2 + parathyroid hormone and fibroblast growth factor-23.
a
Incidence rate is based on the subcohort only.